Biosimilars: Patient and Physician Acceptability is the Fifth Hurdle to Market Competition

dc.contributor.author	Lyles, Alan
dc.date.accessioned	2018-04-03T17:18:51Z
dc.date.available	2018-04-03T17:18:51Z
dc.date.issued	2015
dc.description.abstract	Biosimilar products confront novel market authorization and post-marketing use hurdles. Existing evidence is insufficient to fully address physician and payer acceptability thresholds.	en
dc.format.extent	2 pages	en
dc.genre	journal articles	en
dc.identifier	doi:10.13016/M2NG4GT6B
dc.identifier.citation	Lyles, A., (2015). Biosimilars: Patient and Physician Acceptability is the Fifth Hurdle to Market Competition. Generics and Biosimilars Initiative Journal. 4(1). DOI: 10.5639/gabij.2015.0401.002.	en
dc.identifier.uri	http://hdl.handle.net/11603/7906
dc.language.iso	en	en
dc.publisher	GaBi Journal (Generics and Biosimilars Initiative Journal	en
dc.relation.isAvailableAt	University of Baltimore
dc.subject	acceptability	en
dc.subject	Biologicals	en
dc.subject	Biosimilars	en
dc.subject	interchangeability	en
dc.subject	pricing	en
dc.title	Biosimilars: Patient and Physician Acceptability is the Fifth Hurdle to Market Competition	en
dc.type	Text	en

Files

Now showing 1 - 1 of 1

Name:: Biosimilars- patient and physician acceptability is the fifth hurdle to market competition - GaBI Journal.pdf
Size:: 88.17 KB
Format:: Adobe Portable Document Format
Description:

Now showing 1 - 1 of 1